康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR DTCP-HIB-MCV4 COMBINED VACCINE
Monthly Return of Equity Issuer on Movements in Securities
List of Directors and their Roles and Functions
Articles of Association
POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING; AMENDMENTS TO THE ARTICLES OF ASSOCIATION; ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS; AND ADJUSTMENT TO THE COMPOSITION OF THE COMMITTEES UNDER THE BOARD OF DIRECTORS
Next Day Disclosure Return
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR INHALED TB BOOSTER IN INDONESIA
Form of Proxy for use at the 2025 Second Extraordinary General Meeting to be held on Thursday, November 27, 2025
NOTICE OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING
2025 SECOND EGM CIRCULAR

1 2 3 4 5 6 49